Proguanil is a synthetic antimalarial active pharmaceutical ingredient (API) belonging to the biguanide class of antimalarial compounds. It is primarily used for the prevention and treatment of malaria and is commonly formulated either as Proguanil hydrochloride or in combination with other antimalarial agents. Proguanil is identified by CAS Number 500-92-5, with the molecular formula C11H16N5 and molecular weight 203.29 g/mol.
Proguanil is a biguanide-derived antimalarial compound that has been used extensively in malaria prevention and treatment. Its pharmacological activity is associated with inhibition of the parasite's dihydrofolate reductase pathway, interfering with folate metabolism and parasite development.
For pharmaceutical applications, Proguanil is frequently encountered as Proguanil Hydrochloride, a salt form used in medicinal products. The free base Proguanil and Proguanil Hydrochloride are separate chemical substances and should have their respective CAS numbers, molecular formulas, and molecular weights listed independently.
Proguanil has the following chemical characteristics:
Proguanil is a weak base and its hydrochloride salt is commonly used in pharmaceutical formulations because of its suitable pharmaceutical properties.
Proguanil API is primarily used in antimalarial pharmaceutical products. It is particularly important for malaria chemoprophylaxis and is also used in combination treatment regimens.
Major pharmaceutical applications include:
Proguanil is commonly combined with atovaquone in pharmaceutical products used for malaria prevention and treatment.
Proguanil acts primarily through interference with folate metabolism in malaria parasites. Its active metabolite, cycloguanil, inhibits the parasite enzyme dihydrofolate reductase, disrupting folate-dependent processes required for DNA synthesis and parasite multiplication.
The mechanism contributes to Proguanil's antimalarial activity and explains its use in combination with other antimalarial agents.
Quality control of Proguanil API is important to establish identity, potency, purity, and consistency. Analytical testing should be performed using validated methods and the applicable pharmacopoeial or approved product specification.
Typical analytical evaluations may include:
For pharmaceutical-grade Proguanil, the final acceptance limits should correspond to the applicable official monograph or registered API specification rather than applying a generic research-grade specification.
Proguanil API manufacturing requires controlled chemical processing, appropriate raw-material qualification, impurity control, purification, drying, and analytical testing. Manufacturing controls are important to ensure consistent API quality and reproducible pharmaceutical performance.
A quality-focused Proguanil manufacturing process may include:
Proguanil API can be manufactured according to applicable pharmaceutical standards, regulatory requirements, and customer-specific specifications.
Proguanil should be stored in suitable, tightly closed containers that protect the material from moisture, contamination, and excessive environmental exposure.
Storage conditions should follow applicable stability data and the approved product specification. Appropriate packaging and controlled transportation conditions help maintain API quality throughout its storage and distribution period.
Documentation for Proguanil API may include:
A reliable Proguanil API manufacturing source should maintain controlled production processes, validated analytical testing, impurity monitoring, batch traceability, and appropriate pharmaceutical documentation.
Proguanil is an established antimalarial API with applications in malaria prevention and combination treatment. Consistent manufacturing and quality-control practices help pharmaceutical manufacturers obtain Proguanil API suitable for formulation development and pharmaceutical production.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.5–101.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |